Description:

Sinemet Plus 25mg/100mg Tablets is a combination medication used to treat Parkinson’s disease and parkinsonism syndromes. It relieves symptoms such as rigidity, bradykinesia (slowness of movement), tremor, postural instability, dysphagia, and sialorrhea by replenishing dopamine in the brain—levodopa converts to dopamine, while carbidopa prevents its premature breakdown outside the brain, allowing more effective delivery and reducing peripheral side effects.

Prescription: Prescription-only (Rx). Requires a doctor’s prescription (typically from a neurologist) due to the need for individualized dosing, monitoring for motor fluctuations, and risks like dyskinesia or psychiatric effects.

Therapeutic Category:

Antiparkinsonian agent / Dopaminergic / Levodopa decarboxylase inhibitor combination.

Active Ingredients/Composition: Each tablet contains:

• Carbidopa (equivalent to 25 mg anhydrous carbidopa; often listed as 27 mg monohydrate)
• Levodopa 100 mg (1:4 ratio of carbidopa to levodopa).

Vitamins: None.

Minerals: None.

Variant: 25 mg/100 mg strength (immediate-release; yellow, oval tablet marked ‘650’ on one side, plain on the other; standard maintenance variant; other Sinemet strengths include 10/100, 25/250, and controlled-release forms).

Consume Type:

Oral (tablet; swallow whole with water; can be taken with or without food, but high-protein meals may reduce absorption—space doses from protein if possible).

Directions/Usage: Dosage is individualized and titrated carefully by a doctor to achieve optimal control with minimal side effects.

• Typical starting dose (for patients not previously on levodopa or converting): 1 tablet (25/100) three times daily.
• Maintenance: Often 1 tablet 3-4 times daily or higher (up to 8 tablets/day max, but usually lower; total daily levodopa 300-800 mg common).
• Take at regular intervals (every 4-6 hours while awake). Do not crush/chew unless advised. Avoid abrupt discontinuation. Full effect may take days to weeks. Follow neurologist’s exact regimen; periodic adjustments needed for “wearing-off” or dyskinesia.

Common Side Effects:

• Dyskinesia (involuntary movements), nausea, vomiting (especially early)
• Dizziness, orthostatic hypotension, somnolence/sudden sleep attacks
• Psychiatric: Hallucinations, confusion, anxiety, depression
• Other: Dry mouth, constipation, urine discoloration (dark), anorexia Serious (seek immediate help): Severe hallucinations, impulse control disorders (e.g., gambling), neuroleptic malignant syndrome-like symptoms on withdrawal, or worsening symptoms.

Package Type:

HDPE bottle (often 100 tablets; some markets had blister packs previously, but transitioned to bottles); yellow oval tablets.

Storage Advice: Store below 25-30°C (room temperature), in the original container to protect from light and moisture. Keep tightly closed and out of reach of children.

Safety Advice:

• Not for use in narrow-angle glaucoma, suspicious/undiagnosed skin lesions (melanoma risk), or with non-selective MAOIs (wait 14 days washout).
• Caution in severe cardiovascular/psychiatric disease, peptic ulcer history, or elderly (higher risk of falls/hypotension).
• Monitor for impulse control disorders, hallucinations, or sudden “off” periods.
• Avoid abrupt stop (risk of hyperpyrexia/rigidity).
• Pregnancy/breastfeeding: Use only if benefits outweigh risks—consult specialist.
• May interact with antipsychotics, antihypertensive, iron supplements (reduce absorption).
• Regular follow-up with neurologist required for dose optimization and monitoring.

Product Substitutes: Other carbidopa/levodopa combinations: Generic carbidopa/levodopa 25/100, Sinemet (various strengths), Parcopa (orally disintegrating), Rytary/Sinemet CR (controlled-release), or Stalevo (with entacapone). Alternatives for Parkinson’s: Madopar (levodopa/benserazide), levodopa monotherapy (less common), dopamine agonists (e.g., pramipexole), or MAO-B inhibitors (e.g., rasagiline)—consult neurologist for switch based on symptoms/response.

Manufacturer/Marketer:

Organon Pharma (e.g., Organon Pharma (UK) Limited, Organon Pharma (Ireland) Limited, or Organon LLC; spun off from MSD/Merck in 2021, now markets Sinemet globally).

Country of Origin:

Varies by market/batch—commonly United Kingdom (Organon Pharma UK), Ireland (Organon Ireland), or other EU/US sites (e.g., manufacturing in facilities like Cramlington, UK). In regions like Ghana/Africa, imported from EU/UK or via Organon affiliates/distributors (available in Ghanaian pharmacies, e.g., Trafalgar Gate Pharma listings for Sinemet Plus 25/100).